{"nctId":"NCT02487563","briefTitle":"Prospective Study of Patients With Thrombocytopenia Following HSCT","startDateStruct":{"date":"2015-10"},"conditions":["Thrombocytopenia","Hematologic Diseases"],"count":97,"armGroups":[{"label":"Experimental Group 1","type":"EXPERIMENTAL","interventionNames":["Drug: Decitabine","Drug: rhTPO"]},{"label":"Experimental Group 2","type":"EXPERIMENTAL","interventionNames":["Drug: Decitabine"]},{"label":"Control Group","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Conventional Treatment"]}],"interventions":[{"name":"Decitabine","otherNames":["5-Aza-2'-deoxycytidine"]},{"name":"rhTPO","otherNames":["Thrombopoietin"]},{"name":"Conventional Treatment","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Platelet count ≤ 30 × 109/L persistently at day 60 post-HSCT or later;\n2. Neutrophil and hemoglobin were well recovered;\n3. Full donor chimerism was achieved;\n4. No response to conventional treatments (e.g. thrombopoietin, immunoglobulin, glucocorticoid alone or in combination) for a duration of at least 4 weeks;\n\nExclusion Criteria:\n\n1. Patients with malignancy relapse;\n2. Active infections;\n3. Grade Ⅲ-Ⅳ acute GVHD or severe chronic GVHD according to National Institute of Health criteria;\n4. Severe organ damage;\n5. Thrombosis requiring treatment;\n6. Received decitabine following the current transplantation.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Platelet Count Recovery","description":"Platelet response refers to a sustained increase (stable or increasing level) of at least 30×10E9/L independent of transfusion for 3 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Megakaryocyte Count","description":"The total number of megakaryocytes as well as the platelet-shedding megakaryocytes of bone marrow smears (per cm2) was counted and cross-checked by blinded observers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"7.5","spread":null},{"groupId":"OG002","value":"3.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":30},"commonTop":["Bleeding events","Hypohepatia","Fatigue","Fever","Chest distress"]}}}